María José Rodríguez-Sánchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María José Rodríguez-Sánchez has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Saz-Lara
CarVasCare Research Group, Instituto de Biomedicina, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication - Arturo Martínez-Rodrigo
COMETA Research Group, Informatics Systems Department, University of Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication - Iris Otero-Luis
CarVasCare Research Group, Instituto de Biomedicina, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication - Iván Cavero-Redondo
CarVasCare Research Group, Instituto de Biomedicina, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication - María José Díaz Valentín
CarVasCare Research Group, Faculty of Nursing, University of Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication - María José Simón Saiz
Department of Nursing, University of Castilla-La Mancha, 16071 Cuenca, Spain
1 shared publication
Latest Publications
- Open Access
- 7 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1923
Effect of Remote Ischemic Preconditioning Evaluated by Nurses on Improvement of Arterial Stiffness, Endothelial Function, Diastolic Function, and Exercise Capacity in Patients with Heart Failure with Preserved Ejection Fraction (PIRIC-FEp Study): Protocol for Randomised Controlled Trial
Background/Objectives: Heart failure with preserved ejection fraction (HFpEF) has increased in prevalence as the population ages and associated comorbidities increase. Remote ischemic preconditioning (RIPC) has been shown to provide protection against ischemic injury to the heart and other organs. Therefore, the aim of this project will be to analyse the effectiveness of RIPC in terms of arterial stiffness, endothelial function, diastolic function, and exercise capacity in patients with HFpEF. Methods: The PIRIC-FEp study will be a parallel, randomised controlled trial with two groups conducted at the Faculty of Nursing in Cuenca, University of Castilla-La Mancha. Individuals who are diagnosed with HFpEF and are older than 40 years, with a left ventricular ejection fraction ≥50% and a sedentary lifestyle, will be included. The exclusion criteria will include, among others, patients with noncardiac causes of heart failure symptoms, significant pulmonary disease, diabetes, peripheral vascular disease, or myocardial infarction within the previous three months. A sample size of 48 patients was estimated, with 24 for each group. Participants will be randomly allocated (1:1) to either the RIPC intervention group or the control group to evaluate the effects on arterial stiffness, endothelial function, diastolic function, and exercise capacity. Assessments will be conducted at baseline and after a three-month follow-up period. Results: The findings will be published in a peer-reviewed journal article. Conclusions: This study is important for daily clinical practice because it provides a new approach for the treatment of HFpEF patients via RIPC.
- 7 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1923
Open AccessEffect of Remote Ischemic Preconditioning Evaluated by Nurses on Improvement of Arterial Stiffness, Endothelial Function, Diastolic Function, and Exercise Capacity in Patients with Heart Failure with Preserved Ejection Fraction (PIRIC-FEp Study): Protocol for Randomised Controlled Trial
Background/Objectives: Heart failure with preserved ejection fraction (HFpEF) has increased in prevalence as the population ages and associated comorbidities increase. Remote ischemic preconditioning (RIPC) has been shown to provide protection against ischemic injury to the heart and other organs. Therefore, the aim of this project will be to analyse the effectiveness of RIPC in terms of arterial stiffness, endothelial function, diastolic function, and exercise capacity in patients with HFpEF. Methods: The PIRIC-FEp study will be a parallel, randomised controlled trial with two groups conducted at the Faculty of Nursing in Cuenca, University of Castilla-La Mancha. Individuals who are diagnosed with HFpEF and are older than 40 years, with a left ventricular ejection fraction ≥50% and a sedentary lifestyle, will be included. The exclusion criteria will include, among others, patients with noncardiac causes of heart failure symptoms, significant pulmonary disease, diabetes, peripheral vascular disease, or myocardial infarction within the previous three months. A sample size of 48 patients was estimated, with 24 for each group. Participants will be randomly allocated (1:1) to either the RIPC intervention group or the control group to evaluate the effects on arterial stiffness, endothelial function, diastolic function, and exercise capacity. Assessments will be conducted at baseline and after a three-month follow-up period. Results: The findings will be published in a peer-reviewed journal article. Conclusions: This study is important for daily clinical practice because it provides a new approach for the treatment of HFpEF patients via RIPC.